(2019). Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers. Contemporary Clinical Trials Communications, 100361 - ?. https://doi.org/10.1016/j.conctc.2019.100361